Biolearn – Computational Analysis of Biomarkers

Fall 2025 Application Closed

In collaboration with the Biomarkers of Aging Consortium, we are co-developing Biolearn, an open-source library for biomarkers of aging data analysis. With Biolearn, researchers can easily load public datasets, apply and compare aging clocks/models, and test new computational methods to study biological age and healthspan metrics.

Through this ongoing effort, participants have designed functions and tools that provide insights into biomarkers of aging, enabling researchers to explore DNA methylation data, assess biological clocks, and study age-related biomarkers with precision. Participants have also ported and unified publicly available aging datasets and models, expanding Biolearn’s utility as a comprehensive and standardized platform for aging research.

Apply for exciting endeavor to accelerate advancements in aging research through the power of open-source collaboration! Participants will contribute to the development of the library by implementing aging models, integrating public datasets, and developing analytical tools that enhance the analysis and interpretation of biomarkers of aging.

What You’ll Gain:
• Hands-on experience in open-source software development and data science
• Recognition as an official contributor to Biolearn
• Opportunities to collaborate with longevity researchers and attend exclusive events

Desired Skills:
• Proficiency in Python, object-oriented programming, open-source biological dataset handling.
• Familiarity with Git, and GitHub, Jupyter Notebooks
• Interest in aging research, software engineering, bioinformatics, or computational biology.

Thematic Series on Aging

Nucleate x Aging Initiative

In collaboration with Nucleate, the Aging Initiative hosts thematic event series that bring together leading voices across science, biotech, and public health to explore the frontiers of aging and longevity. Each series highlights a different focus area in the field — from aging clocks and computational tools to therapeutics, biotech ventures, and translational pathways.